reception an light business lunch served in the
conference room, Aquis Grana
City Hotel Aachen
A. Challenges in designing neuroprotection trials for HD
In this section general problems and challenges for HD
neuroprotection trials will be discussed
brief history of HD neuroprotection trials and the
lessons gained grom it (Berry Kremer)
outcome measures: clinical, imaging and
biomarker approaches (Bernhard Landwehrmeyer)
approaches to design clinical trials: introduction to
adaptive study designs (Wilhelm Gaus)
B. How to select the favourite drug
What mechanisms to go for?
In this section supporters of any particular
mentioned will defend theri favourite mechanism and
list the possible drugs readily available for future trials
- NMDA receptor antagonists
- Mitochondrial boosters
- Free radical scavengers
- Aggragation inhibitors
- HDAC inhibitors
- Dopamine antagonists
- Adenosine 2A antagonists
- Growth factors
- Fatty acids
- What else?
to subscribe to one of the mechanisms mentioned)
17:30 - 18:00
Large scale systematic screening (Collin Hovinga for SET-HD
- Defining criteria for ideal drug data
Dinner at Restaurant Elisenbrunnen, Aachen
9:00 - 10:00
systematic screening (continued) (Collin Hovinga for SET-HD
assessment of the list of drugs with effects on HD in human or disease models
- The SET-HD
drug reviews -> How far are we? What is missing?
C. The next
steps (structured discussion)
B. Kremer und C. Kosinski
10:00 - 10:15
Necessity for further preclinical testing?
10:15 - 10:30
Are we ready for a recommendation of clinical trials?
clinical trial type?
are possible financial resources?
aims for the next meeting
to split up work and organisation of next face to
business lunch served in the conference room